How effective is h3n2 clade 14 vaccine

1. The question being asked — and what the sources actually cover

The user’s phrase “H3N2 clade 14 vaccine” appears to request how well a vaccine matched to a specific H3N2 genetic group protects; none of the supplied documents reference a “clade 14” vaccine or clade 14 circulation, so the reporting must be read as evidence about vaccine effectiveness (VE) against H3N2 more broadly and, in particular, against the newly dominant subclade K (formerly J.2.4.1) that has diverged from the Northern Hemisphere vaccine reference strains ^{[1] [2] [5]}.

2. How well current vaccines perform against the emergent H3N2 subclade K (the closest analog in the reporting)

Multiple analyses and surveillance briefs show that VE in H3N2-dominant seasons is typically lower than for other subtypes and that a mismatch reduces protection; early network estimates and journal reports put VE in broad H3N2 seasons in the low-to-moderate range — for example outpatient VE ≈42% and hospitalization VE ≈55% against A(H3N2) in U.S. networks for 2024–25, while meta-analyses and season-to-season summaries often find overall seasonal VE between roughly 30%–60% ^{[6] [3] [7]}. Some hospital-based analyses even showed VE that crossed the null for H3N2 in certain age groups (19%, CI crossing zero) during 2023–24, highlighting variability by season and timing since vaccination ^[4].

3. Evidence specific to subclade K and why the vaccine might be less effective

Genetic and antigenic characterization indicates subclade K carries multiple HA mutations that make it antigenically distinct from the vaccine reference viruses selected earlier in 2025, and early hemagglutination-inhibition and ferret-serum data suggested low reactivity with antisera raised to the Northern Hemisphere vaccine strains — an observation that raises the prospect of reduced VE against clinical disease from K viruses ^{[1] [2] [5]}. Surveillance from countries where K dominated (for example Australia’s heavy season) and expert commentary warn that H3N2-dominant seasons tend to show lower vaccine effectiveness and more severe illness in older adults ^[8].

4. What protection remains — severe disease, children, and vaccine platforms

Despite antigenic drift, multiple public-health summaries and reporting emphasize that vaccines still tend to protect better against severe outcomes (hospitalization, death) than against mild medically attended illness, and some early estimates suggest meaningful protection: adults’ VE against medically attended severe disease was estimated in some early analyses at ~32–39% while estimates in children were higher (~72–75%) in preliminary reports noted by global health outlets ^{[3] [6] [9]}. New vaccine platforms show promise — a modified mRNA influenza vaccine demonstrated superiority over a control vaccine with a relative efficacy of 34.5% against influenza-like illness in a clinical trial setting — but such trial results mix strains and do not map one-to-one to protection against a single emergent subclade ^[10].

5. Bottom line, gaps, and what would answer the “clade 14” question

Taken together, the evidence in the provided reporting says: when H3N2 drifts away from the vaccine strain (as with subclade K), overall VE against any symptomatic infection tends to be modest (often 30%–50% range) and variable by age and time since vaccination, while protection against severe outcomes is usually better and remains the primary public-health justification for vaccination ^{[3] [6] [4]}. However, because none of the supplied sources mention “clade 14” or a vaccine targeted specifically to it, no direct estimate for an “H3N2 clade 14 vaccine” can be given from this material; answering that precise query would require genetic/antigenic data and VE analyses tied to clade 14 specifically, which are not present in the provided reporting ^{[1] [2]}.